首页> 外文期刊>Nephron >Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.
【24h】

Endotoxin-free dialysate improves response to erythropoietin in hemodialysis patients.

机译:不含内毒素的透析液可改善血液透析患者对促红细胞生成素的反应。

获取原文
获取原文并翻译 | 示例
           

摘要

Background/Aims: Inflammatory process induced by endotoxin is one of the causes of resistance to recombinant human erythropoietin (rHuEPO) in hemodialysis patients. Thus dialysate contaminated with endotoxin may diminish response to rHuEPO. We investigated whether dose of rHuEPO could be reduced with endotoxin-free ultrafiltered dialysate. Methods: Twenty-seven chronic hemodialysis patients receiving rHuEPO were studied. The patients did not have known causes of anemia other than chronic renal failure. An endotoxin-cut polyethylene ultrafilter was installed into the dialysate fluid circuit. Hematocrit and dose of rHuEPO were monitored before and after installation. Dose of rHuEPO was adjusted to keep hematocrit at about 30%. Endotoxin concentration of dialysate was measured by commercial limulus test (Endospecy((R))). Results: After installation of ultrafilter, dialysate endotoxin concentration decreased from >100 to <1.0 endotoxin units/liter (EU/l). Dose of rHuEPO decreased from 90.0 U/kg/week (median) to 57.3 U/kg/week (p < 0.05) and hematocrit increased from 30.3% (median) to 32.2% (p = 0.03) after 5 months of installation of ultrafilter. The running cost of the ultrafilter corresponded to only 4% of the cost of spared rHuEPO. Conclusions: Ultrafiltered endotoxin-free dialysate caused significant reduction in dose of rHuEPO to keep target hematocrit level. Endotoxin-cut ultrafilter was beneficial to hemodialysis patients in medical and in economical aspects.
机译:背景/目的:内毒素诱导的炎症过程是血液透析患者对重组人促红细胞生成素(rHuEPO)产生耐药性的原因之一。因此,被内毒素污染的透析液可能会降低对rHuEPO的反应。我们研究了无内毒素超滤透析液是否可以降低rHuEPO的剂量。方法:研究了27例接受rHuEPO治疗的慢性血液透析患者。除慢性肾功能衰竭外,患者没有其他已知的贫血原因。将内毒素切割的聚乙烯超滤器安装到透析液回路中。在安装前后监测血细胞比容和rHuEPO剂量。调节rHuEPO的剂量以使血细胞比容保持在约30%。通过商业试验(Endospecy)测量透析液的内毒素浓度。结果:安装超滤器后,透析液内毒素浓度从> 100降至<1.0内毒素单位/升(EU / l)。在安装超滤器5个月后,rHuEPO的剂量从90.0 U / kg /周(中位数)降低到57.3 U / kg /周(p <0.05),血细胞比容从30.3%(中位数)增加到32.2%(p = 0.03)。 。超滤器的运行成本仅相当于剩余的rHuEPO成本的4%。结论:超滤无内毒素透析液可显着降低rHuEPO剂量,以保持目标血细胞比容水平。内毒素切割超滤器在医学和经济方面对血液透析患者有益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号